Abstract:Purpose: Metformin, widely used for the treatment of diabetes mellitus (DM), has shown potential for inhibiting abdominal aortic aneurysm (AAA) growth by reducing extracellular matrix remodeling and inflammation. However, its influence on clinical outcomes and aneurysm sac dynamics after endovascular aneurysm repair (EVAR) remains uncertain. This retrospective study aims to explore the effects of metformin on long-term outcomes following EVAR. Materials and methods: Patients who underwent elective standard EVAR for infrarenal AAA at a single academic Dutch hospital from 2000 to 2022 were included. We collected baseline patient demographics, comorbid conditions, anatomical and operative characteristics, and 30-day postoperative events. Metformin use was defined as using it preceding EVAR. The primary outcome, the postoperative aneurysm sac volume over time, was investigated using linear mixed-effects modeling. The secondary outcomes, 8-year all-cause mortality and freedom from graft-related events, were evaluated using Kaplan-Meier methods. Results: We analyzed 685 patients, including 634 (93%) non-metformin users and 51 (7%) metformin users. The median follow-up period was similar (4.0 years [IQR=1.5, 6.5] vs 5.0 years [IQR=2.0, 8.0]; p=0.091). Patients on metformin had a preoperative aneurysm sac volume of 153 cc (IQR=114, 195) compared with 178 cc (IQR=133, 240) for non-metformin patients (p=0.054). At 30 days post-EVAR, metformin patients had a comparable mean aneurysm sac volume compared with non-metformin patients (metformin: -19.4 cc [95% confidence interval [CI]: -47.4, 8.5]; p=0.173). The effect of metformin on aneurysm growth over time was not significant (-3.9 cc/year; [95% CI: -22.7, 14.9]; p=0.685). Following risk-adjusted analysis, metformin use was associated with similar rates of all-cause mortality (metformin vs no metformin: 50% vs 44%; hazard ratio [HR]=1.11, 95% CI: 0.66, 1.88; p=0.688) and freedom from graft-related events (metformin vs no metformin: 63% vs 66%; HR=1.82, 95% CI: 0.98, 3.38; p=0.059). Conclusion: Although metformin use may reduce preoperative AAA growth, it does not seem to influence overall/long-term post-EVAR AAA sac dynamics, all-cause mortality, or freedom from graft-related events. These findings suggest that the potential protective effect of metformin on AAA may not be sustained after EVAR. Further prospective studies are needed to investigate the mechanisms underlying the potential role of metformin in AAA management following EVAR. Clinical impact: There is currently no approved pharmacological treatment available to slow the abdominal aortic aneurysm (AAA) growth rate and reduce the related risk of rupture. In our retrospective analysis including 685 patients undergoing EVAR for infrarenal AAA, we found that metformin use was not associated with improved post-EVAR outcomes, such as a reduction of aneurysm sac volume over time, eight-year all-cause mortality, or freedom of graft-related events. These findings suggest that the potential protective effect of metformin on AAA may not be sustained after EVAR and underscore the need for ongoing research into this area.

Inhibition of angiotensin-induced aortic aneurysm by metformin in apolipoprotein E-deficient mice

Metformin Does Not Attenuate Angiotensin II-Induced Abdominal Aortic Aneurysms in Low-Density Lipoprotein Receptor-Deficient Mice

Abstract 058: Efficacy and Mechanisms of Metformin Therapy in Established Experimental Abdominal Aortic Aneurysms

Mechanisms and efficacy of metformin-mediated suppression of established experimental abdominal aortic aneurysms

Netrin-1 Monoclonal Antibody-Functionalized Nanoparticle Loaded with Metformin Prevents the Progression of Abdominal Aortic Aneurysms

[Metformin inhibits aortic atherosclerosis in mice by regulating actin skeleton in vascular smooth muscle cells]

Metformin Improves the Function of Abdominal Aortic Aneurysm Patient-Derived Aortic Smooth Muscle Cells

Could Metformin use reduce abdominal aortic aneurysm risk? A Mendelian randomisation study using known Metformin targets

Association of metformin use with abdominal aortic aneurysm: A systematic review and meta-analysis

Metformin Inhibited Nod-like Receptor Protein 3 Inflammasomes Activation and Suppressed Diabetes-Accelerated Atherosclerosis in Apoe−/− Mice

The Protective Effect of Metformin on Abdominal Aortic Aneurysm: A Systematic Review and Meta-Analysis

Patient-derived microphysiological model identifies the therapeutic potential of metformin for thoracic aortic aneurysm

Metformin prescription and aortic aneurysm: systematic review and meta-analysis.

Metformin Prescription and Aortic Aneurysm: Systematic Review and Meta-Analysis

Metformin inhibits intracranial aneurysm formation and progression by regulating vascular smooth muscle cell phenotype switching via the AMPK/ACC pathway

Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis.

Metformin Attenuates Plaque-Associated Tau Pathology and Reduces Amyloid-Β Burden in APP/PS1 Mice

Metformin Use and Long-term Outcomes Including Aneurysm Sac Dynamics Following EVAR for Infrarenal Abdominal Aortic Aneurysm: "A Retrospective Study"

Metformin-Loaded Alginate Nanoparticles Inhibits Mouse Atherosclerosis by Regulating Macrophage Differentiation by Activating the Adenosine Monophosphate-Activated Protein Kinase/Signal Transducer and Activator of Transcription 3 Pathway

Metformin Limits Osteoarthritis Development and Progression Through Activation of AMPK Signalling

Metformin Inhibits the Phenotypic Transformation of Aortic Vascular Smooth Muscle Cells Induced by Hyperglycemia Through Regulation of the Mir-21-mediated PTEN/pAKT/Egr-1 Pathway